Mutation analysis from the REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV. 2. Juni 2012 Schirmacher, P., Schuette, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Zaun, S., Dietel, M., 2012. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases–a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. Schimanski, C.C., Mohler, M., Schon, M., van Cutsem, E., Greil, R., Bechstein, W.O., Hegewisch-Becker, S., von Wichert, G., Vohringer, M., Heike, M., Heinemann, V., Peeters,… Weiterlesen MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy. Staehler, MD, Bergmann, L., Grünwald, V., Huschke, T., Keilholz, U., Ohlmann, C., Stöckle, M., Weigang-Koehler, K., Hauswald, K., Schaller, F., Strassl, L., Junker, K., 2012. Weiterlesen